Barely Significant
← all excerpts

Neoadjuvant Toripalimab Plus Axitinib for Nonmetastatic Clear Cell Renal Cell Carcinoma With Tumor Thrombus: A Combined Analysis of Two Phase II Clinical Trials.

MedComm (2020) · 2026 · PMC13053665 · PMID 41953639

Europe PMCDOI
1
hedged sentence
0.0890
closest p · 1.8× alpha
0.0890
boldest claim

The sentences

did not reach statistical significancep = 0.089so close (0.05 < p ≤ 0.1)
showed a trendp = 0.089so close (0.05 < p ≤ 0.1)
Although the CD8+/PD‐1+ T cell showed a trend toward a higher proportion in the nonresponders, the difference did not reach statistical significance ( p = 0.089). 2.6 Follow‐Up and Subgroup Analyses With a median follow‐up of 36.1 (IQR: 25.0–44.9) months, the median disease‐free survival (DFS) and overall survival (OS) were not reached (Table 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.